neurosense-tx.com (NRSN) Year-over-year earnings per share growth for the last twelve months
Short-term drivers for NeuroSense Therapeutics (NRSN) are linked to the publication of new drug trial data, while operating losses are already priced in. Global scaling potential is based on the patenting of neurodegeneration treatments. The current level of quarterly EPS growth captured revenue dynamics, where the parameter stabilized at 59.40. The company's advantage lies in the development of PrimeC, which slows paralysis in ALS through molecular synergy.
Summary analytical data breakdowns for NeuroSense Therapeutics (NRSN)
- market value and analyst target forecast:
- market capitalization details:
- book capitalization data:
- debt level and financial liquidity data:
Debt to Equity NeuroSense Therapeutics|NRSN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital neurosense-tx.com|NRSN - Company Cumulative Debt|Debt to Book Value NeuroSense Therapeutics, Ltd.|NRSN - Company Long-Term Loans and Borrowings|Company Current Liabilities NeuroSense Therapeutics|Quick Ratio neurosense-tx.com
- earnings and valuation multiples indicators:
NRSN - Final Profit|Projected Future Earnings NeuroSense Therapeutics|NRSN - Market Cap to Earnings|Future Price to Earnings neurosense-tx.com|NRSN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple NeuroSense Therapeutics, Ltd.|NRSN - Operating profit EBITDA|Earnings per share for the last twelve months NeuroSense Therapeutics|NRSN - Earnings per one share for the last 12 months|Quarterly EPS earnings growth neurosense-tx.com|NRSN - Earnings per share growth rate in current year|Expected earnings per share growth for next year NeuroSense Therapeutics
Comprehensive company analysis:NeuroSense Therapeutics Ltd, NRSN
NeuroSense Therapeutics (NRSN), led by Alon Ben-Nun, focuses on high-tech therapies for ALS and neurodegenerative diseases, which require strict resource management. By analyzing the quarterly EPS growth efficiency metric on GURU.Markets, an investor can observe the actual dynamics of net income per share, which filters out market noise and currency distortions, allowing for an objective assessment of the business's fundamental value and preventing overpayment for the asset.
Who NeuroSense Therapeutics competes with
Biogen (BIIB) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Neurocrine (NBIX)|Year-over-year earnings per share growth for the last twelve months Regencell|Axsome Corp (AXSM) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth ACAD|XENE - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Viking Therapeutics, Inc. VKTX|SUPN: Year-over-year earnings per share growth for the last 12 months|CPRX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Denali Corp DNLI|HRMY: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months biohavenpharma.com (BHVN)|Year-over-year net earnings per share growth for the last 12 months AMLX|TRVI: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months PRAX (Praxis Medicines)|Year-over-year earnings per share growth rate for the last twelve months AVXL|Quarterly EPS earnings growth CBLL (CeriBell, Inc.)|Year-over-year earnings per one share growth for the last 12 months PRTA|Alector Therapeutics - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Annexon Biosciences|omeros.com (OMER) - Year-over-year earnings per share growth for the last twelve months|Neurogene Therapeutics - Year-over-year earnings per one share growth for the last 12 months|ACIU (AC Immune) - Quarterly EPS earnings growth|Quarterly EPS earnings growth voyagertherapeutics.com|Year-over-year earnings per share growth for the last twelve months Neumora Therapeutics, Inc. (NMRA)|SCLX: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth TVGN (Tevogen Bio Holdings, Inc.)|Alpha Cognition Inc (ACOG) - Earnings per share growth in annualized terms for the last twelve months|CGTX: Year-over-year net earnings per share growth for the last 12 months|IKT - Quarterly EPS earnings growth|SAVA (Cassava Sciences) - Year-over-year net earnings per share growth for the last 12 months|ASRT: Year-over-year earnings per share growth rate for the last twelve months|COYA (Coya Therapeutics Inc) - Quarterly EPS earnings growth|VistaGen Therapeutics Inc (VTGN) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth OVID|Year-over-year net earnings per share growth for the last 12 months acumenpharm.com ABOS|Year-over-year earnings per share growth for the last twelve months CervoMed CRVO|Year-over-year net earnings per share change for the last twelve months Alterity Therapeutics Ltd. (ATHE)|CLNN - Year-over-year earnings per share growth for the last twelve months|PEPG (PepGen Inc.) - Year-over-year earnings per share growth for the last 12 months|Jupiter Neurosciences (JUNS) - Year-over-year earnings per share growth for the last twelve months|relmada.com - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Annovis Bio|Grace Tx (GRCE) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Firefly Neuroscience Inc (AIFF)|anewmeds.com - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Reviva Pharmaceuticals RVPH|MTVA: Year-over-year earnings per share growth for the last 12 months|NeurAxis - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Helius Medical|PASG (passagebio.com) - Year-over-year net earnings per share growth for the last 12 months|Neuphoria Therapeutics (NEUP) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Minerva Neurosciences|ATHA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Addex Therapeutics Ltd (ADXN)|ALZN - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Cyclerion Therapeutics, Inc. CYCN|PTIX: Year-over-year earnings per share growth for the last 12 months|Pasithea - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Cortigent, Inc.|ATXI (Avenue Therapeutics, Inc.) - Year-over-year net earnings per share growth for the last 12 months|Brainstorm Cell Therapeutics Inc. (BCLI) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Cara Therapeutics, Inc|CHRO: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Eliem Therapeutics (ELYM)|ITCI - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Longboard Pharmaceuticals, Inc. LBPH|Year-over-year net earnings per share change for the last twelve months Marinus Pharmaceuticals Inc (MRNS)|NKGen - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months NeuroBo Pharma|Sage Therapeutics, Inc. (SAGE) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months SNPX|Year-over-year earnings per share growth for the last twelve months Trevena|Vigil Neuro (VIGL) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth WENA|CERE - Earnings per share growth in annualized terms for the last twelve months
